EOLS / Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of c more_horizontal

Evolus, Inc. provides medical aesthetic products and competes against Botox with its main product, Jeuveau. The company is gaining market share and co more_horizontal

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.38 per sh more_horizontal

Evolus, Inc., a pharmaceutical company specializing in aesthetic products, faces significant challenges with its lead product Jeuveau, a treatment for more_horizontal

Evolus, Inc. (NASDAQ:EOLS ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants David Erickson - VP, IR David Moatazedi - Pre more_horizontal

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of more_horizontal

Evolus, Inc. (NASDAQ:EOLS ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants David Erickson - Vice President of Investor more_horizontal

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -14.29% and 0.39%, respectively, for the quarter ended December 2022. Do the numbers h more_horizontal